SCHEMBL285035

SCHEMBL285035

OCCC(O)OCC(O)CO

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.52
LMNA P02545 4/20 0.40
ALDH1A1 P00352 1/20 0.40
USP2 O75604 1/20 0.34
CYP1A2 P05177 2/20 0.31
KDM4E B2RXH2 2/20 0.31
AGTR1 P30556 1/20 0.31
DUSP3 P51452 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27899741 0.89 THRB (0.42) THRBLMNAALDH1A1
SCHEMBL1524615 0.88 THRB (0.40) THRBLMNAALDH1A1USP2KDM4E
SCHEMBL10894591 0.86 THRB (0.39) THRBLMNAALDH1A1USP2KDM4E
SCHEMBL11042187 0.84 USP2 (0.37) THRBLMNAALDH1A1USP2KDM4E
SCHEMBL10786690 0.84 USP2 (0.37) THRBLMNAALDH1A1USP2KDM4E
SCHEMBL1357902 0.83 LMNA (0.44) THRBLMNAALDH1A1USP2CYP1A2
SCHEMBL1206579 0.83 USP2 (0.44) THRBLMNAALDH1A1USP2CYP1A2
SCHEMBL17237504 0.81 USP2 (0.34) THRBLMNAALDH1A1USP2CYP1A2
SCHEMBL1619852 0.79 LMNA (0.40) THRBLMNAALDH1A1USP2CYP1A2
SCHEMBL11236220 0.79 TDP1 (0.40) THRBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215552-A1 DERIVATIVES OF 1,3-PROPANEDIOL Vantage Specialty Chemicals, Inc. (US) 2017-09-13 EP claimed
WO-2016040956-A1 DERIVATIVES OF 1,3-PROPANEDIOL VANTAGE SPECIALTY CHEMICALS, INC. (US) 2016-03-17 WO claimed
US-20240026407-A1 MODIFICATION OF SAPONINS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-01-25 US disclosed
WO-2023242187-A1 ENZYMATIC MODIFICATION OF SAPONINS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-12-21 WO disclosed
US-20220126258-A1 COMPOSITIONS AND FORMULATIONS FOR ENTRAPPING PROTEIN ON A SURFACE PURE TRANSPLANT SOLUTIONS L L C (US) 2022-04-28 US disclosed
US-11260363-B2 Compositions and methods for entrapping protein on a surface PURE TRANSPLANT SOLUTIONS L.L.C. (US) 2022-03-01 US disclosed
US-20200147580-A1 COMPOSITIONS AND METHODS FOR ENTRAPPING PROTEIN ON A SURFACE PURE TRANSPLANT SOLUTIONS L.L.C. 2020-05-14 US disclosed
US-10556218-B2 Compositions and methods for entrapping protein on a surface PURE TRANSPLANT SOLUTIONS L.L.C. (US) 2020-02-11 US disclosed
US-20190039041-A1 COMPOSITIONS AND METHODS FOR ENTRAPPING PROTEIN ON A SURFACE GENOMICS USA, INC. (US) 2019-02-07 US disclosed
EP-2997037-B1 USE OF A COMPOSITION FOR ENTRAPPING A PROTEIN ON A SURFACE GENOMICS USA INC (US) 2018-11-21 EP disclosed
US-10105674-B2 Compositions and methods for entrapping protein on a surface GENOMICS USA, INC. (US) 2018-10-23 US disclosed
EP-1581617-B8 METHODS FOR PRODUCING END-PRODUCTS FROM CARBON SUBSTRATES DANISCO US INC (US) 2011-03-23 EP disclosed
US-20100285548-A1 Process And Apparatus For The Microbial Production Of A Specific Product And Methane AGRAFERM TECHNOLOGIES AG (DE) 2010-11-11 US disclosed
US-20090075347-A1 Production of Bacterial Strains Cross Reference To Related Applications GENENCOR INTERNATIONAL, INC. 2009-03-19 US disclosed
WO-2004109729-A1 LOW FREEZING ELECTROLYTE FOR AN ELECTROLYTIC CAPACITOR KEMET ELECTRONICS CORPORATION (US) 2004-12-16 WO disclosed
US-5164459-A METHOD FOR TREATING THE SURFACE OF AN ABSORBENT RESIN NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) 1992-11-17 US disclosed
EP-0357673-A4 ANTIBIOTIC REUTERIN 1991-09-25 EP disclosed
EP-0357673-A1 ANTIBIOTIC REUTERIN. PROBIOLOGICS INT INC (US) 1990-03-14 EP disclosed
CN-1032618-A TOBACCO SMOKING ARTICLE BLOCKERS C A INC (US) 1989-05-03 CN disclosed
WO-1988008452-A1 ANTIBIOTIC REUTERIN PROBIOLOGICS INTERNATIONAL, INC. (US) 1988-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240026407-A1 MODIFICATION OF SAPONINS GBA3, SI, MANBA THRB 2563/4885LMNA 1587/4885ALDH1A1 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.